The significance of targeting biofilms cannot be overstated. Biofilms are structured communities of bacteria encased in a self-produced matrix of polysaccharides, proteins, and extracellular DNA. Within this matrix, bacteria adopt gene expression profiles that differ dramatically from their free-floating, planktonic counterparts, altering their morphology, surface properties, and susceptibility to antibiotics. Cells buried in a biofilm are shielded by enzymatic degradation of antimicrobials, active efflux pumps, and reduced permeability, which is why biofilm-associated infections on catheters, ventilators, and implants so often defy standard treatment regimens. Among the virulence factors that govern this process in A. baumannii, the biofilm-associated protein known as Bap, encoded by the bap gene, plays a critical role in adhesion to bronchial cells, structural integrity of the biofilm, and the development of water channels that distribute nutrients through the community. Disrupting bap has been shown to reduce biofilm thickness, volume, and interbacterial adhesion, making it an attractive molecular target.

In the new study, published in MicrobiologyOpen, the team collected 100 clinical isolates of A. baumannii from patients at a burn hospital affiliated with Mazandaran University of Medical Sciences. The isolates came from wounds, urine, and blood samples of 50 male and 50 female patients ranging in age from six months to 88 years, distributed across adult burn, intensive care, surgical, and pediatric burn units. Wound samples accounted for the majority of isolates at 73 percent, followed by urine at 15 percent and blood at 12 percent. Identification was confirmed through conventional microbiological and biochemical methods as well as polymerase chain reaction targeting the blaOXA-51 beta-lactamase gene, a molecular signature of the species. The researchers then used a microtiter plate crystal violet staining assay to classify each isolate as a weak, moderate, or strong biofilm producer.

The nanoparticles themselves were produced through green synthesis, an approach in which plant extracts serve as both reducing and capping agents. Phytochemicals such as flavonoids, terpenoids, and polysaccharides donate electrons to reduce silver ions into metallic silver nanoparticles while simultaneously stabilizing their surfaces. This method is cost-effective, environmentally sustainable, and avoids the toxic solvents associated with conventional chemical synthesis. Nepeta pogonosperma, a member of the Lamiaceae family identified in 1984, has a long history in traditional medicine across Iran and neighboring regions, where it has been used to treat conditions ranging from pneumonia and influenza to stomach disorders and asthma. Astrodaucus persicus, a member of the Apiaceae family native to Asia, has traditionally been consumed as a food additive in Iran and Turkey, and plants in this family exhibit antibacterial, hepatoprotective, antitumor, and apoptosis-inducing activities.

When the researchers measured the minimum inhibitory and minimum bactericidal concentrations of the two nanoparticle formulations, the results were striking. MIC and MBC values against the 100 clinical isolates ranged from 0.1 to 40 micrograms per milliliter, but for more than 94 percent of isolates these values fell between 0.1 and 3 micrograms per milliliter. For AgNP@Ap, the Astrodaucus persicus formulation, 80 of the isolates were inhibited at concentrations of 0.1 to 0.5 micrograms per milliliter, while the Nepeta formulation inhibited 52 isolates at that same low range. A significant correlation emerged between biofilm formation intensity and susceptibility: over 90 percent of strong and moderate biofilm producers exhibited MIC and MBC values between 0.1 and 3 micrograms per milliliter, suggesting that the most dangerous biofilm-forming strains were also the most vulnerable to the nanoparticles.

At sub-inhibitory concentrations of 1 microgram per milliliter for AgNP@Ap and 1.171 micrograms per milliliter for AgNP@Np, both formulations interfered with biofilm development in the 20 strongest producers. For AgNP@Ap, 40 percent of isolates showed 41 to 60 percent inhibition of new biofilm formation and 10 percent showed inhibition exceeding 80 percent. AgNP@Np performed comparably, with 30 percent of isolates showing 41 to 60 percent inhibition and 10 percent showing greater than 80 percent inhibition. Crucially, the nanoparticles did not merely prevent new biofilms from forming; they also dismantled established ones. When pre-formed biofilms were treated, 45 percent of isolates exposed to AgNP@Ap showed 41 to 60 percent disruption, and 50 percent of those exposed to AgNP@Np fell into the same category, with some isolates experiencing up to 80 percent or greater biomass loss.

The molecular analysis revealed why these effects matter. Among the 100 isolates, 93 exhibited elevated bap gene expression, with fold-changes spanning from 2-fold to as high as 20-fold relative to the reference strain. Every isolate showing more than a 5-fold increase was a strong biofilm producer, and statistical testing confirmed that strong biofilm formers expressed bap at significantly higher levels than weaker producers. When the strong producers were treated with sub-MIC concentrations of the nanoparticles, bap expression dropped significantly compared with untreated controls at both 24 and 48 hours, with the reduction becoming more pronounced at the longer exposure. Quantitative real-time PCR with the 16S rRNA gene as an internal control, analyzed using the comparative 2^-ΔΔCt method, documented these changes precisely. Notably, isolates with higher baseline bap expression tended to have lower MIC and MBC values, indicating greater susceptibility to the nanoparticles.

The authors emphasize that these green-synthesized particles are not simply bits of metallic silver. Prior characterization showed that AgNP@Np particles are spherical, with an average crystallite size of 31.68 nanometers, a hydrodynamic diameter of 233 nanometers, and a zeta potential of −35.1 millivolts indicating good colloidal stability. Fourier-transform infrared spectroscopy confirmed that polyphenols, carbohydrates, and amides from the plant extract form an organic corona around the silver core. These capping molecules are not inert; many phytochemicals possess intrinsic antibacterial, anti-adhesion, and quorum-sensing inhibitory activities. The anti-biofilm efficacy observed is therefore likely the product of synergy between the silver core, which disrupts bacterial membranes, generates reactive oxygen species, and interferes with transcriptional machinery, and the bioactive plant-derived surface layer, which may modulate the sustained release of bactericidal silver ions. Differences in the phytochemical profiles of the two plants—polyphenols and flavonoids in Nepeta versus monoterpenes and benzodioxole compounds in Astrodaucus—likely explain the subtle variations in performance between the two formulations.

The findings arrive at a moment when the clinical urgency of A. baumannii infections has never been greater, particularly for burn patients and intensive care populations, where biofilm-mediated persistence drives mortality. Because silver nanoparticles target multiple biological pathways simultaneously, the likelihood of resistance developing is reduced compared with single-target antibiotics, and prior studies have documented similar effects, including reductions in bap expression with chemically synthesized silver nanoparticles at higher concentrations. The consistency of the present results, achieved at lower concentrations in multidrug-resistant clinical isolates rather than laboratory strains, strengthens the case for clinical relevance. The authors caution, however, that translating these nanoparticles into practice requires further work: precise mechanisms of action, long-term safety profiles, potential side effects, and integration into medical devices and treatment protocols all remain to be established. Still, the study offers compelling evidence that an eco-friendly, low-cost synthesis route rooted in traditional medicinal plants can disarm one of the hospital’s deadliest pathogens at the level of its own genes.

Subject of Research: Plant-based silver nanoparticles as anti-biofilm agents against Acinetobacter baumannii

Article Title: Effect of Green‐Synthesized Silver Nanoparticles From Nepeta pogonosperma and Astrodaucus persicus on the Reduction of Bap Gene Expression in Strong Biofilm‐Producing Acinetobacter baumannii Clinical Isolates

Article References: Kakavan, M., Gholami, M., Ahanjan, M., Ebrahimzadeh, M. A., Hossein Nataj, A., Mousavi, T., & Goli, H. R. (2026). Effect of Green‐Synthesized Silver Nanoparticles From Nepeta pogonosperma and Astrodaucus persicus on the Reduction of Bap Gene Expression in Strong Biofilm‐Producing Acinetobacter baumannii Clinical Isolates. MicrobiologyOpen, 15(5), Article e70391. https://doi.org/10.1002/mbo3.70391

Image Credits: AI Generated

DOI: 10.1002/mbo3.70391

Keywords: Acinetobacter baumannii, silver nanoparticles, green synthesis, biofilm, bap gene, antimicrobial resistance, Nepeta pogonosperma, Astrodaucus persicus, qRT-PCR, nosocomial infections, nanomedicine, ESKAPE pathogens

Pseudomonas aeruginosa is one of medicine’s most formidable opponents. This Gram-negative bacterium accounts for roughly ten to eleven percent of all hospital-acquired infections and can strike the lungs, bloodstream, urinary tract, eyes, and skin, with particular menace for immunocompromised patients. It belongs to the notorious ESKAPE group of pathogens and resists treatment through multiple overlapping strategies: enzymes that destroy antibiotics, altered drug targets, reduced membrane permeability, active efflux pumps, and protective biofilms. The World Health Organization has designated it a priority pathogen, and recent surveillance has documented a steady rise in carbapenem-resistant strains between 2014 and 2024, driven by the organism’s remarkable genetic plasticity and its propensity for horizontal gene transfer.

The core problem the researchers set out to address is a diagnostic blind spot. Traditional phenotypic susceptibility testing, whether by disk diffusion or automated systems, measures what a bacterium does under laboratory conditions, not what it is genetically capable of doing. Molecular panels, meanwhile, only look for pre-established markers and can miss novel or situation-specific determinants. Phenotype-based approaches are slow and open to interpretation, while targeted molecular methods are costly and limited in scope. Neither reliably detects silent resistance determinants or early adaptive changes, which means a patient’s infection may appear treatable on paper while the underlying genome tells a more troubling story.

The investigation began with 1,295 culture-positive Pseudomonas aeruginosa specimens collected at the Central Laboratory of IMS and SUM Hospital in Odisha between January 2023 and December 2024. All isolates underwent antimicrobial susceptibility testing using both the Kirby-Bauer disk diffusion method and the VITEK-2 automated system, following CLSI and EUCAST standards. Multidrug resistance was defined using the internationally recognized Magiorakos criteria. To select representative strains for deep sequencing, the team applied principal component analysis and hierarchical clustering across twelve antibiotics, calculating a resistance burden score for each isolate. From this landscape they chose three isolates spanning the spectrum: two multidrug-resistant strains, designated 0040 and 1609, and one largely susceptible non-MDR isolate, 0727, drawn from diverse specimen sources including urine, pus, and tracheal aspirates, and from both hospital- and community-acquired settings.

Species identity was confirmed by 16S rRNA sequencing, and genomic DNA was sequenced on an Illumina NovaSeq platform using paired-end reads. After quality trimming with Trimmomatic, cleaned reads were mapped to the well-characterized PA14 reference genome with BWA-MEM, achieving greater than 92 percent coverage at 30-fold depth for all three isolates. Variant calling with the GATK HaplotypeCaller applied deliberately stringent filters, retaining only high-confidence homozygous alternate variants with perfect allele frequency, and SnpEff annotated the functional consequences. Notably, none of the isolates carried loss-of-function mutations in the mismatch repair genes mutS, mutL, or uvrD, ruling out a hypermutator state and indicating that the elevated variant loads reflected deep lineage divergence rather than runaway mutation. Resistance genes were identified against the Comprehensive Antibiotic Resistance Database using strict confidence thresholds that admitted only perfect and strict hits.

The genomic arithmetic told a striking story. The multidrug-resistant isolates diverged from PA14 by approximately 69,000 variants, compared with roughly 58,700 for the non-MDR strain, indicating substantial evolutionary separation despite superficially similar phenotypes among the resistant pair. In the MDR isolates, genotype and phenotype agreed closely across five antibiotic classes. Their resistance was anchored by beta-lactamase variants PDC-67 and OXA-396, chromosomal enzymes that become dangerous when regulatory adaptations amplify their output. Crucially, the team detected variants in the regulatory elements ArmR and cprS, which are known to drive overexpression of these beta-lactamases, providing a coherent mechanistic explanation for the observed multidrug resistance.

The non-MDR isolate 0727 told a very different and more unsettling tale. Despite being susceptible to most antibiotic classes in phenotypic testing, it carried a gyrA T83I mutation, a well-known fluoroquinolone resistance-associated change, along with the PDC-1 and OXA-847 beta-lactamase variants. None of these determinants were expressed as measurable resistance. The pattern constitutes what the researchers call a silent resistome: resistance genes present and intact but transcriptionally dormant or functionally masked, perhaps awaiting regulatory shifts, efflux upregulation, or stress-mediated induction to switch on. Similar genotype-phenotype discordance has been documented in Shigella and in Gram-negative uropathogens, reinforcing the emerging consensus that gene presence alone does not equal resistance, and that quinolone resistance in particular typically requires synergistic factors beyond single point mutations.

To place these clinical isolates in global context, the team constructed a phylogenetic tree from 454 genomes, combining their three isolates, the PA14 reference, and 450 publicly available assemblies selected for quality and recency. Pairwise distances computed with Mash revealed that the two MDR isolates clustered tightly in a single clade with short terminal branches, indicating recent common ancestry and minimal divergence between them, embedded among publicly available clinical genomes. The closest neighbor to this pair was a 2021 clinical isolate from South Korea. In contrast, isolate 0727 occupied a distinct terminal branch in a separate clade, grouping most closely with diverse lineages that included a 2007 cystic fibrosis isolate from Denmark, a pattern consistent with weaker antibiotic selection and greater phylogenetic spread among susceptible strains. The findings echo prior work showing that hospital-derived resistant strains often form compact phylogenetic groups under shared selective pressure, raising the possibility of common transmission pathways that would require formal epidemiological tracing to confirm.

The study also surfaced an intriguing metabolic signal. The MDR isolates produced only diffuse fluorescent green pigmentation in broth culture, while the non-MDR strain displayed a stronger greenish-blue pigment gradient, differences the authors link cautiously to the metabolic cost of sustaining resistance. Maintaining efflux pumps and drug-destroying enzymes is energetically expensive, and previous research has shown that multidrug-resistant strains often suppress costly secondary metabolites such as pyocyanin to conserve resources for survival. The authors stress that these pigment observations are visual only and require quantitative biochemical confirmation, but they add a compelling dimension to the picture of resistance as an adaptation with measurable physiological trade-offs.

The clinical implications are sobering. A phenotypically susceptible isolate can carry latent determinants with the theoretical potential to become active under antibiotic pressure, meaning that a seemingly safe treatment choice could, in principle, select for emergence of resistance from within the infecting population. The authors argue that genomic data should be integrated into surveillance alongside phenotypic testing, and they call for transcriptomic studies to reveal how silent resistomes are regulated and when they might be roused. They acknowledge the limitations of sequencing only three isolates from a single institution and emphasize that larger, longitudinally sampled collections with functional validation are needed. Still, their strategy of using multivariate phenotypic screening to select a small, representative subset for whole-genome sequencing offers a practical template for resource-limited settings, where sequencing every isolate remains out of reach. As antimicrobial resistance accelerates worldwide, this study makes clear that what diagnostic labs cannot see in a Petri dish may already be written in the bacterial genome, waiting for its moment.

Beyond the immediate findings, the study illustrates how reference-guided sequencing workflows can be adapted to routine clinical laboratories. By mapping reads against the well-characterized PA14 reference rather than attempting full de novo assembly, the researchers kept computational demands modest while still resolving tens of thousands of variants, an approach that smaller hospital laboratories in low- and middle-income settings could realistically adopt as sequencing costs continue to fall.

The reliance on the Comprehensive Antibiotic Resistance Database also underscores a broader shift in resistance detection. Curated databases with defined confidence levels allow laboratories to distinguish high-confidence resistance determinants from ambiguous hits, reducing the false alarms that have historically plagued in silico resistance prediction. This standardization is becoming increasingly important as genomic surveillance programs expand globally and as public health agencies move toward harmonized interpretation of resistance genotypes.

The phylogenetic placement of the isolates carries practical weight as well. Tight clustering of the multidrug-resistant pair, alongside a clinical isolate from South Korea, fits a pattern increasingly documented worldwide in which resistant hospital strains spread across borders through patient movement, medical tourism, or shared equipment lineages. Distinguishing such imported or transmitted clones from locally evolved ones is central to infection control, and the Mash-based distance approach used here offers a rapid screen for that purpose.

Finally, the silent resistome concept reframes how susceptibility results should be read. A susceptible report reflects conditions in a growth medium at a single moment, not the full adaptive potential encoded in the genome. As regulatory shifts, efflux changes, or selective pressure during therapy can awaken dormant determinants, longitudinal monitoring of patients and institutional surveillance that pairs phenotypic testing with periodic sequencing may become essential to anticipate resistance before it emerges at the bedside.

Subject of Research: Genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa characterized by comparative whole-genome sequencing.

Article Title: Comparative genomics reveals genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa

Article References: Comparative genomics reveals genotype-phenotype concordance and cryptic resistomes in clinical Pseudomonas aeruginosa. (n.d.). https://doi.org/10.1007/s10123-026-00892-3

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00892-3

Keywords: Pseudomonas aeruginosa, antimicrobial resistance, whole-genome sequencing, multidrug resistance, silent resistome, genotype-phenotype concordance, beta-lactamase, phylogenetics, hospital-acquired infection, genomic surveillance, ESKAPE pathogens, gyrA mutation

The antimicrobial peptide LL-37, derived from human cathelicidin, represents a fascinating candidate for combating these formidable foes. Known for its broad-spectrum activity against various microbes, LL-37 also possesses anti-inflammatory properties that may be advantageous in therapeutic applications. However, the precise mechanisms through which LL-37 operates against such resistant strains have yet to be fully elucidated, making this study particularly crucial.

In their work, Eladl and collaborators employed detailed biophysical characterization techniques to analyze the behavior of LL-37 peptides in the presence of agar and artificial membranes. Through these experiments, they aimed to determine how the antimicrobial peptide interacts with and disrupts bacterial membranes, a key factor in its effectiveness against drug-resistant strains. Such insights can pave the way for designing more effective antimicrobials or improving existing therapies.

Moreover, the researchers conducted transcriptomic analyses to study the genetic responses of multidrug-resistant E. coli when exposed to LL-37. This part of the study unveiled the significant shifts in gene expression that occur when these bacteria encounter the antimicrobial peptide. Understanding the molecular pathways activated in response to LL-37 is vital for developing strategies to enhance its efficacy and mitigate any potential resistance development.

The challenge posed by ESKAPE pathogens, characterized by their ability to evade the immune response and resist multiple antibiotics, necessitates innovative research approaches. Pathogens such as Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species form a formidable group in hospital settings, often leading to serious infections that are difficult to treat. LL-37’s activity against such pathogens raises hopes for new treatment avenues, especially given its unique mechanism of action.

One of the primary appeals of LL-37 is its capacity to induce permeabilization of bacterial membranes without relying solely on classical antibiotic mechanisms. Traditional antibiotics typically target specific bacterial processes such as cell wall synthesis or protein production, which can lead to the development of resistance. In contrast, LL-37 appears to disrupt the integrity of the cell membrane, making it a promising candidate to potentially sidestep the resistance pathways that bacteria have developed.

The implications of this research extend beyond understanding LL-37’s direct antimicrobial effects. The modulation of the host immune response by LL-37 presents an additional avenue for exploration. The peptide has been shown to exhibit immunomodulatory effects, potentially enhancing the body’s ability to combat infections while also reducing inflammation. These dual effects could be immensely beneficial in treating infections caused by multidrug-resistant organisms.

Furthermore, understanding how LL-37 affects gene expression in resistant E. coli may help identify new targets for antibiotic development. As the study reveals shifts in expression patterns, it could guide researchers towards alternative pathways that can be exploited either by developing new drugs or repurposing existing ones to work in conjunction with LL-37.

Future research inspired by Eladl’s findings could also explore how the stability of LL-37 in various biological environments affects its antimicrobial efficacy. Investigating how factors like pH, temperature, and the presence of serum proteins influence the peptide’s activity would provide crucial insights necessary for its clinical application. Ensuring the peptide remains active in the complex human body while effectively reaching its target is a key challenge in turning such promising laboratory results into real-world therapies.

In conclusion, Eladl’s pioneering work on LL-37-derived antimicrobial peptides unveils significant potential for addressing the growing threat of multidrug-resistant pathogens. By elucidating the biophysical interactions and transcriptomic responses of these novel therapeutic candidates, this study paves the way for exciting advancements in antimicrobial research. The battle against drug-resistant bacteria is ongoing, and studies like this bring renewed hope in the quest for innovative solutions.

As the scientific community continues to confront the rising problem of antimicrobial resistance, ongoing research will be essential to unlock the full potential of novel antimicrobial compounds like LL-37. By combining rigorous characterization with an understanding of the underlying biological mechanisms, future developments could revolutionize our approach to treating some of the most challenging infections known today.

Subject of Research: Antimicrobial peptide LL-37 against drug-resistant Escherichia coli and ESKAPE pathogens

Article Title: Biophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens.

Article References:

Eladl, O. Biophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens.
Sci Rep 15, 36126 (2025). https://doi.org/10.1038/s41598-025-22890-7

Image Credits: AI Generated

DOI: 10.1038/s41598-025-22890-7

Keywords: Antimicrobial peptides, LL-37, multidrug resistance, E. coli, ESKAPE pathogens, biophysical characterization, transcriptomic analysis.